PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis

Angiogenesis

Volumn 11, Issue 4, 2008, Pages 361-367

  Aljada, Ahmad ^b   O'Connor, Laura ^a   Fu, Yu Yen ^b   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Endothelial cell migration; Peroxisome proliferator activated receptor gamma agonist; Pioglitazone; Rosiglitazone; Vascular endothelial growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR; PIOGLITAZONE; ROSIGLITAZONE; VASCULOTROPIN; VITRONECTIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELLS, CULTURED; CHEMOTAXIS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; PPAR GAMMA; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58149335340     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-008-9118-0     Document Type: Article

References (48)

1. JA Laukkanen DE Laaksonen L Niskanen E Pukkala A Hakkarainen JT Salonen 2004 Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study Cancer Epidemiol Biomarkers Prev 13 1646 1650
2. SS Coughlin EE Calle LR Teras J Petrelli MJ Thun 2004 Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults Am J Epidemiol 159 1160 1167 10.1093/aje/kwh161
3. KT Khaw N Wareham S Bingham R Luben A Welch N Day 2004 Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study Cancer Epidemiol Biomarkers Prev 13 915 919
4. M Inoue M Iwasaki T Otani S Sasazuki M Noda S Tsugane 2006 Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan Arch Intern Med 166 1871 1877 10.1001/archinte.166.17.1871
5. BJ Veldt W Chen EJ Heathcote H Wedemeyer J Reichen WP Hofmann 2008 Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus Hepatology 47 1856 1862 10.1002/hep.22251
6. E Saez P Tontonoz MC Nelson JG Alvarez UT Ming SM Baird 1998 Activators of the nuclear receptor PPARgamma enhance colon polyp formation Nat Med 4 1058 1061 10.1038/2042
7. E Mueller P Sarraf P Tontonoz RM Evans KJ Martin M Zhang 1998 Terminal differentiation of human breast cancer through PPAR gamma Mol Cell 1 465 470 10.1016/S1097-2765(00)80047-7
8. P Tontonoz L Nagy JG Alvarez VA Thomazy RM Evans 1998 PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 93 241 252 10.1016/S0092-8674(00)81575-5
9. L Nagy P Tontonoz JG Alvarez H Chen RM Evans 1998 Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma Cell 93 229 240 10.1016/S0092-8674(00)81574-3
10. P Escher W Wahli 2000 Peroxisome proliferator-activated receptors: insight into multiple cellular functions Mutat Res 448 121 138 10.1016/S0027-5107(99)00231-6
11. K Yajima H Hirose H Fujita Y Seto H Fujita K Ukeda 2003 Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice Am J Physiol Endocrinol Metab 284 E966 E971
12. VG Keshamouni DA Arenberg RC Reddy MJ Newstead S Anthwal TJ Standiford 2005 PPAR-gamma activation inhibits angiogenesis by blocking ELR + CXC chemokine production in non-small cell lung cancer Neoplasia 7 294 301 10.1593/neo.04601
13. M Kolak H Yki-Jarvinen K Kannisto M Tiikkainen A Hamsten P Eriksson 2007 Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes J Clin Endocrinol Metab 92 720 724 10.1210/jc.2006-1465
14. RJ Jha 1999 Thiazolidinediones-the new insulin enhancers Clin Exp Hypertens 21 157 166
15. HE Lebovitz MA Banerji 2001 Insulin resistance and its treatment by thiazolidinediones Recent Prog Horm Res 56 265 294 10.1210/rp.56.1.265
16. (2000) Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin. Diabetes Technol Ther 2:290-291
17. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 932 936 10.1038/nature04478
18. W Risau 1997 Mechanisms of angiogenesis Nature 386 671 674 10.1038/386671a0
19. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 10.1126/science.1104819
20. A De Luca A Carotenuto A Rachiglio M Gallo MR Maiello D Aldinucci 2008 The role of the EGFR signaling in tumor microenvironment J Cell Physiol 214 559 567 10.1002/jcp.21260
21. SA Mousa LJ O'Connor JJ Bergh FB Davis TS Scanlan PJ Davis 2005 The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin J Cardiovasc Pharmacol 46 356 360 10.1097/01.fjc.0000175438.94906.a0
22. RW Colman RA Pixley IM Sainz JS Song I Isordia-Salas SN Muhamed 2003 Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen J Thromb Haemost 1 164 170 10.1046/j.1538-7836. 2003.00025.x
23. J Bozarth M Penno 1997 SAM: an improved method for the quantitation of cellular migration-role of avb3 integrin in endothelial and smooth muscle cell migration Methods Cell Sci 19 179 187 10.1023/A:1009789416463
24. T Lemberger B Desvergne W Wahli 1996 Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology Annu Rev Cell Dev Biol 12 335 363 10.1146/annurev.cellbio.12.1.335
25. JC Fruchart P Duriez B Staels 1999 Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis Curr Opin Lipidol 10 245 257 10.1097/00041433-199906000-00007
26. KM Suchanek FJ May JA Robinson WJ Lee NA Holman GR Monteith 2002 Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231 Mol Carcinog 34 165 171 10.1002/mc.10061
27. J Engel J Rabba D Schild 1996 A transient, RCK4-like K+ current in cultured Xenopus olfactory bulb neurons Pflugers Arch 432 845 852 10.1007/s004240050207
28. X Xin S Yang J Kowalski ME Gerritsen 1999 Peroxisome proliferator- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo J Biol Chem 274 9116 9121 10.1074/jbc.274.13.9116
29. N Marx T Bourcier GK Sukhova P Libby J Plutzky 1999 PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease Arterioscler Thromb Vasc Biol 19 546 551
30. H Satoh K Tsukamoto Y Hashimoto N Hashimoto M Togo M Hara 1999 Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function Biochem Biophys Res Commun 254 757 763 10.1006/bbrc.1998.0126
31. D Panigrahy S Huang MW Kieran A Kaipainen 2005 PPARgamma as a therapeutic target for tumor angiogenesis and metastasis Cancer Biol Ther 4 687 693
32. T Murata S He M Hangai T Ishibashi XP Xi S Kim 2000 Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization Invest Ophthalmol Vis Sci 41 2309 2317
33. S Goetze F Eilers A Bungenstock U Kintscher P Stawowy F Blaschke 2002 PPAR activators inhibit endothelial cell migration by targeting Akt Biochem Biophys Res Commun 293 1431 1437 10.1016/S0006-291X(02)00385-6
34. S Goetze A Bungenstock C Czupalla F Eilers P Stawowy U Kintscher 2002 Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands Hypertension 40 748 754 10.1161/01.HYP.0000035522.63647.D3
35. H Huang SC Campbell DF Bedford T Nelius D Veliceasa EH Shroff 2004 Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510 Mol Cancer Res 2 541 550
36. D Panigrahy S Singer LQ Shen CE Butterfield DA Freedman EJ Chen 2002 PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis J Clin Invest 110 923 932
37. MR Sierra-Honigmann AK Nath C Murakami G Garcia-Cardena A Papapetropoulos WC Sessa 1998 Biological action of leptin as an angiogenic factor Science 281 1683 1686 10.1126/science.281.5383.1683
38. S Giannini M Serio A Galli 2004 Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity J Endocrinol Invest 27 982 991
39. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 1011 1027 10.1200/JCO.2005.06.081
40. RG Fahmy CR Dass LQ Sun CN Chesterman LM Khachigian 2003 Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth Nat Med 9 1026 1032 10.1038/nm905
41. KJ Kim B Li J Winer M Armanini N Gillett HS Phillips 1993 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 841 844 10.1038/362841a0
42. W Yan B Bentley R Shao 2008 Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis Mol Biol Cell 19 2278 2288 10.1091/mbc.E07-10-1068
43. L Michalik B Desvergne W Wahli 2004 Peroxisome-proliferator-activated receptors and cancers: complex stories Nat Rev Cancer 4 61 70 10.1038/nrc1254
44. A Kaipainen MW Kieran S Huang C Butterfield D Bielenberg G Mostoslavsky 2007 PPARalpha deficiency in inflammatory cells suppresses tumor growth PLoS ONE 2 e260 10.1371/journal.pone.0000260
45. D Panigrahy A Kaipainen S Huang CE Butterfield CM Barnes M Fannon 2008 PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition Proc Natl Acad Sci USA 105 985 990 10.1073/pnas.0711281105
46. HD Strickler J Wylie-Rosett T Rohan DR Hoover S Smoller RD Burk 2001 The relation of type 2 diabetes and cancer Diabetes Technol Ther 3 263 274 10.1089/152091501300209633
47. R Govindarajan L Ratnasinghe DL Simmons ER Siegel MV Midathada L Kim 2007 Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes J Clin Oncol 25 1476 1481 10.1200/JCO.2006.07.2777
48. LQ Shen A Child GM Weber J Folkman LP Aiello 2008 Rosiglitazone and delayed onset of proliferative diabetic retinopathy Arch Ophthalmol 126 793 799 10.1001/archopht.126.6.793